PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
9497016-9	1998	This could suggest that the combination of D2/5HT2 receptor blockade contributes to the antipsychotic effect and a low incidence of EPS seen with quetiapine in comparative phase three trials.	Quetiapine Fumarate	146-156	5-hydroxytryptamine receptor 2A	Homo sapiens	46-59	
24830305-0	2014	Neocortical serotonin2A receptor binding predicts quetiapine associated weight gain in antipsychotic-naive first-episode schizophrenia patients.	Quetiapine Fumarate	50-60	5-hydroxytryptamine receptor 2A	Homo sapiens	12-32	
24830305-6	2014	Quetiapine was chosen because it is characterized by a moderately high affinity for the serotonin2A receptor and a fast dissociation rate from the dopamine D2 receptor.	Quetiapine Fumarate	0-10	5-hydroxytryptamine receptor 2A	Homo sapiens	88-108	
24068825-4	2013	Quetiapine is an atypical antipsychotic agent with a complex pharmacology, including antagonist actions at 5-HT2A and, to a lesser extent, D2 receptors.	Quetiapine Fumarate	0-10	5-hydroxytryptamine receptor 2A	Homo sapiens	107-113	
20614105-0	2011	Serotonin2A receptor blockade and clinical effect in first-episode schizophrenia patients treated with quetiapine.	Quetiapine Fumarate	103-113	5-hydroxytryptamine receptor 2A	Homo sapiens	0-20	
22519923-5	2012	The antidepressant effects of quetiapine are poorly understood, but may be related to antagonism of 5-HT2A receptors in cortical regions, partial agonism of 5-HT1A in the prefrontal cortex in association with increased extracellular dopamine release in the region, or to reduced synaptic reuptake of noradrenaline resulting from inhibition of the noradrenaline reuptake transporter by the quetiapine metabolite norquetiapine.	Quetiapine Fumarate	30-40	5-hydroxytryptamine receptor 2A	Homo sapiens	100-106	
22419526-3	2012	The atypical antipsychotics clozapine and quetiapine, which have affinity for 5-HT(2A) and 5-HT(1A) receptors, are effective against visual hallucinations in PD.	Quetiapine Fumarate	42-52	5-hydroxytryptamine receptor 2A	Homo sapiens	78-86	
22037407-2	2012	As an atypical antipsychotic medication with antagonist activity at D1 and D2, 5-HT(1A) and 5-HT(2A), H(1) and alpha1 and alpha2 receptors, quetiapine has been found to decrease impulsivity in other psychiatric disorders but its effects on impulsivity have not been studied in alcohol dependent patients.	Quetiapine Fumarate	140-150	5-hydroxytryptamine receptor 2A	Homo sapiens	94-99	
21487653-2	2011	Quetiapine, an atypical antipsychotic medication with antagonist activity at D1 and D2, 5-HT(1A) and 5-HT(2A), H(1), and alpha1 and alpha2 receptors was shown to promote abstinence, reduce drinking days, and reduce heavy drinking days in a 12-week double-blind placebo-controlled trial.	Quetiapine Fumarate	0-10	5-hydroxytryptamine receptor 2A	Homo sapiens	103-108	
20614105-4	2011	Moreover, we investigated possible relationships between clinical efficacy, oral dose, and plasma levels of quetiapine RESULTS: Significant nonlinear relationships were found between serotonin2A receptor occupancy, quetiapine dose, and plasma concentration.	Quetiapine Fumarate	108-118	5-hydroxytryptamine receptor 2A	Homo sapiens	183-203	
20887583-2	2010	Quetiapine, a multiple receptor antagonist at 5-HT(1A) and 5-HT(2A), dopamine D(1) and D(2), histamine H(1), and adrenergic alpha(1) and alpha(2) receptors, is an atypical antipsychotic medication that has recently shown promise for the treatment of alcoholism.	Quetiapine Fumarate	0-10	5-hydroxytryptamine receptor 2A	Homo sapiens	61-66	
16855458-1	2006	Quetiapine is a novel and atypical antipsychotic agent with serotonin 5-HT2A antagonism higher than D2 blockade.	Quetiapine Fumarate	0-10	5-hydroxytryptamine receptor 2A	Homo sapiens	70-76	
18224291-6	2008	Several studies have suggested that quetiapine-induced mania/hypomania may be associated with frontal dopamine release via serotonin 5HT2A receptor blockade.	Quetiapine Fumarate	36-46	5-hydroxytryptamine receptor 2A	Homo sapiens	123-147	
17563257-7	2007	Quetiapine enhances central serotonergic neurotransmission via its high affinity for serotonergic receptors (e.g., 5-HT2A receptor antagonism and partial agonistic activity at the 5-HT1A receptor).	Quetiapine Fumarate	0-10	5-hydroxytryptamine receptor 2A	Homo sapiens	115-130	
19300555-6	2007	This receptor occupancy profile with relatively higher affinity for the 5HT(2A) receptor compared with the D(2) receptor is in part responsible for the antipsychotic characteristics and low incidence of extrapyramidal side-effects of quetiapine.	Quetiapine Fumarate	234-244	5-hydroxytryptamine receptor 2A	Homo sapiens	72-88	
12397853-4	2002	Clozapine, olanzapine, quetiapine, and ziprasidone cause minimal effects on prolactin levels in adults, which may be due to a higher 5-HT2A:D2 binding ratio and differential effects on dopamine neurotransmission, with less interference in the tuberoinfundibular pathway.	Quetiapine Fumarate	23-33	5-hydroxytryptamine receptor 2A	Homo sapiens	133-139	
11512044-0	2001	In vivo 5-HT2A receptor blockade by quetiapine: an R91150 single photon emission tomography study.	Quetiapine Fumarate	36-46	5-hydroxytryptamine receptor 2A	Homo sapiens	8-23	
11512044-2	2001	METHOD: 5-HT2A binding was estimated using 123I-5-I-R91150 and single photon emission tomography (SPET) in six schizophrenic subjects treated with quetiapine at a mean (+/-SD) daily dose of 350+/-123 mg for at least 5 weeks and a matched sample of six healthy volunteers.	Quetiapine Fumarate	147-157	5-hydroxytryptamine receptor 2A	Homo sapiens	8-14	
11512044-5	2001	RESULTS: Quetiapine treatment resulted in a significant decline in 5-HT2A receptor availability in the frontal cortex (mean 0.98+/-0.09) relative to healthy volunteers (mean 1.33+/-0.16).	Quetiapine Fumarate	9-19	5-hydroxytryptamine receptor 2A	Homo sapiens	67-82	
11512044-8	2001	CONCLUSION: Quetiapine treatment results in significant in vivo blockade of cortical 5-HT2A, similar to other atypical antipsychotic drugs.	Quetiapine Fumarate	12-22	5-hydroxytryptamine receptor 2A	Homo sapiens	85-91	
11313155-0	2001	D(2) and 5HT(2A) receptor occupancy of different doses of quetiapine in schizophrenia: a PET study.	Quetiapine Fumarate	58-68	5-hydroxytryptamine receptor 2A	Homo sapiens	9-25	
11313155-7	2001	Quetiapine induced a consistently higher degree of 5HT(2A) receptor occupancy, with mean occupancies of 74 and 57% at doses of 750 and 450 mg/day, respectively.	Quetiapine Fumarate	0-10	5-hydroxytryptamine receptor 2A	Homo sapiens	51-67